First generic capecitabine approved for colorectal and breast cancers

September 18, 2013

FDA has approved the oral chemotherapy tablet capecitabine, the first generic version of Teva’s Xeloda, to treat cancer of the colon or rectum that has spread to other parts of the body. It also approved generic capecitabine for treatment of metastatic breast cancer.

FDA has approved the oral chemotherapy tablet capecitabine, the first generic version of Teva’s Xeloda, to treat cancer of the colon or rectum that has spread to other parts of the body. It also approved generic capecitabine for treatment of metastatic breast cancer. 

Teva Pharmaceuticals USA has gained FDA approval to market generic capecitabine in 150- and 500-mg strengths.